SkinBioTherapeutics PLC Research programme with University of Manchester (7484U)
April 08 2021 - 1:00AM
UK Regulatory
TIDMSBTX
RNS Number : 7484U
SkinBioTherapeutics PLC
08 April 2021
08 April 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
New research programme initiated with University of
Manchester
SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that it has initiated a research
programme with the University of Manchester ("the University") to
investigate and develop microbiome formulations that support
natural anti-inflammatory response to a range of environmental
challenges. Expanding the collaboration with the University was one
of the areas of investment laid out by the Company when it raised
funds via placing and open offer in October 2020.
The programme, which will run for two years, will focus on how
the microbiome can influence and rebalance the body's response to
inflammation in skin health and skin disease. The immune system, as
the body's biological defence system, is able to recognise
potentially damaging agents, remove them and trigger repair.
Inflammation is a key component of this immune response. However,
immune response can sometimes become overstimulated and this can
lead to chronic inflammation which is characteristic of some skin
diseases e.g. atopic dermatitis, acne and rosacea. Prolonged
inflammation is also associated with chronic, non-healing
wounds.
T he microbiome, which is known to be linked with the
inflammatory process, its activation and control pathways, offers a
potential route to supporting the natural immune inflammatory
response within products such as sunscreens. In February 2019, the
US FDA issued guidance to remove two common ingredients from
cosmetics and sunscreens (aminobenzoic acid and trolamine
salicylate), and is in the process of evaluating further safety
data on 12 other widely used ingredients, with many of the
chemicals detected on the skin and in blood weeks after
application(1, 2) . This has created a need within the sunscreen
and cosmetics industries for more naturally derived ingredients
that could support the body's immune inflammatory response to
different environmental challenges.
Working with the translational dermatology team at Manchester
University, SkinBioTherapeutics has already identified a number of
inflammatory pathways of interest, and routes to target these
pathways with microbiome-derived regulators. Subject to a positive
programme outcome, the Company intends to pursue commercialisation
of any identified bacterial formulations through their addition to
existing third party products or the development of new products
targeted at specific conditions.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"This research programme with the University of Manchester aims
to widen our understanding of the role that the microbiome plays
within the immune system, and how it can be used to support the
body's natural immune response. Similarly to our approach with the
AxisBiotix food supplement, we hope to eventually bring
immune-supporting microbiome formulations to market through
everyday products, such as skin lotions and creams, where we see an
increasing consumer preference for natural ingredients. This is an
exciting new area of research for us and has the potential to
broaden our skin health pipeline further."
Prof Cath O'Neill, CSO of SkinBioTherapeutics said:
"There is now an extensive growing body of research
demonstrating direct links between the microbiome and the immune
system, and consequently skin health. The Company is in the middle
of a food supplement study and the potential modifying effect on
skin conditions, such as psoriasis. However, with this new line of
research, we have the opportunity to assess the powerful effect of
the microbiome on the immune system and skin health."
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
(1.) https://www.fda.gov/media/124654/download
(2.) https://www.ewg.org/sunscreen/report/the-trouble-with-sunscreen-chemicals/
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUCGCUPGGRM
(END) Dow Jones Newswires
April 08, 2021 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024